KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Repligen (RGEN) Other financing activities (2020 - 2025)

Repligen (RGEN) has disclosed Other financing activities for 6 consecutive years, with -$2.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Other financing activities rose 9.51% to -$2.1 million in Q4 2025 year-over-year; TTM through Sep 2025 was -$225000.0, a 105.47% decrease, with the full-year FY2023 number at $7.3 million, changed N/A from a year prior.
  • Other financing activities was -$2.1 million for Q4 2025 at Repligen, down from $1.5 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $12.3 million in Q1 2022 to a low of -$15.8 million in Q4 2022.
  • A 5-year average of $58166.7 and a median of $372000.0 in 2021 define the central range for Other financing activities.
  • Peak YoY movement for Other financing activities: crashed 1164.3% in 2022, then skyrocketed 2451.52% in 2024.
  • Repligen's Other financing activities stood at -$1.3 million in 2021, then plummeted by 1164.3% to -$15.8 million in 2022, then surged by 68.89% to -$4.9 million in 2023, then surged by 51.96% to -$2.4 million in 2024, then increased by 9.51% to -$2.1 million in 2025.
  • Per Business Quant, the three most recent readings for RGEN's Other financing activities are -$2.1 million (Q4 2025), $1.5 million (Q3 2025), and $676000.0 (Q2 2025).